Latest Blogs

Apr 02, 2020
Dr. Martina Murphy, Dr. Devika Das, and Dr. Elizabeth Henry consider how the COVID-19 pandemic is affecting hematology/oncology training, and offer tips for staying connected to trainees.
Apr 01, 2020
Dr. Mona Hassan arrived in the United States excited for professional development and activism opportunities. Within a week, COVID-19 completely derailed her plans.
Apr 01, 2020
The TMPRSS2 protein has a role in both COVID-19 and in prostate cancer, suggesting intriguing avenues of inquiry for researchers engaged in the fight against COVID-19.
Mar 31, 2020
Dr. Inas Abuali attempts to make sense of the shifting tides and what they mean for her patients, colleagues, and loved ones (while maintaining safe social distance from her co-fellows).
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO. Prior to this role, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Aug 07, 2018
I spoke with our current ASCO president about her theme for the year, her work with the Alliance for Clinical Trials in Oncology, and her frontier spirit.
Jul 16, 2018
Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.
Jul 09, 2018
I am really pleased to have with us ASCO's Chief Medical Officer and Senior Vice President for a conversation focusing on right-to-try policies.
Jun 29, 2018
At the most recent Board of Directors meeting, we heard insightful presentations from participants in the Leadership Development Program, pivoted toward the execution of our 5-year strategic plan, and had a valuable conversation with NCI director Dr. Norman Sharpless.
May 24, 2018
While more biosimilars will likely be available in oncology in the next several years, their specific impact on patient care is going to depend on patient and provider acceptance of these agents.
May 17, 2018
ASCO would like to inform you of some changes to MOC that are a direct result of your input and our open, transparent collaboration with the ABIM. 

Pages